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ABSTRACT
Background: The intestinal microbiota plays an important role in the pathogenesis of 
Clostridioides difficile-associated diarrhea, and regional and racial characteristics influence 
the microbiome composition and diversity. We investigated the intestinal microbiome 
characteristics of patients with C. difficile colitis (CD+) compared to those of patients with 
colitis not due to C. difficile (CD−), patients with vancomycin-resistant enterococci (VRE) 
colonization, and healthy controls, in Korea.
Materials and Methods: We collected stool samples from 24, 18, 11 and 13 subjects within 
CD+, CD−, VRE and healthy control groups, respectively. The microbial communities were 
evaluated by 454-pyrosequencing of bacterial 16s rRNA.
Results: The species richness and microbial diversity were significantly lower in the CD+ group 
compared to those in healthy controls, but not compared to those in CD− and VRE groups. 
Phylum-level analysis showed that the proportion of Actinobacteria in the CD+ group was 
significantly lower than in the healthy control, but was unchanged compared to that in CD− 
and VRE groups. At the genus level, compared to the healthy group, the CD+ group showed 
significantly lower proportions of Blautia, Bifidobacterium, Faecalibacterium et al. Compared to the 
VRE group, the CD+ group showed a significantly higher proportion of Anaerostipes.
Conclusions: We could identify the intestinal microbiome characteristics of Koreans with 
C. difficile colitis. It might help to develop microbiome based diagnostic and treatment 
modalities.
Keywords: Faecal microbiota; Intestinal microbiota; Clostridioides difficile infection;  
Next generation sequencing
INTRODUCTION
The human gut microbiota plays an important role in nutrition and physiology, and is closely 
related to health and disease [1, 2]. The gut microbial composition differs depending on age, 
geography, lifestyle, and health status [2-4]. The methods of analysing human gut microbiota 
have rapidly advanced as new technologies have been developed; in particular, next 
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generation sequencing (NGS) plays a key role in improving our perspective on gut microbiota 
[5]. The characteristics of the gut microbiota in health and disease have been extensively 
studied, and their importance in intestinal diseases such as inflammatory bowel disease, as 
well as various systemic diseases such as diabetes, obesity, and cardiovascular disease, has 
been established [6-8].
Clostridioides difficile infection (CDI) is a major focus of research in the study of gut microbiota 
[9]. Despite the recent major increase in the incidence and severity of CDI, treatment with 
antibiotics such as metronidazole and oral vancomycin have remained the most effective 
strategy [10]. However, in recurrent CDI, antibiotic treatment is associated with a high 
recurrence rate [11]. Recently, van Nood et al. reported the first randomized controlled trial 
of faecal microbiota transplantation (FMT) in patients with recurrent CDI. FMT showed 
much better treatment outcomes than antibiotic treatment [12]. This indicated that CDI 
is associated with a collapse of the healthy gut microbiota, and that faecal material from a 
healthy donor can restore the gut microbiota of patients [13]. Currently, an important focus 
of research is the investigation of the nature of microbial changes in CDI patients, and is 
connected with the development of new treatment strategies that are more effective and 
convenient [14].
In Korea, the incidence of CDI is also increasing; FMT has been introduced to treat recurrent and 
refractory CDI [15]. However, there is a lack of research studying the gut microbiota of healthy 
people and patients with CDI in Korea. The characteristics of the gut microbiota differ in different 
countries; therefore, it is necessary to investigate the characteristics of the gut microbiome in 
Korean subjects. Several studies showed the characteristics of the gut microbiome in healthy 
Korean populations have significant differences from other countries [16, 17].
VRE and C. difficile are both major nosocomial pathogens and thus have similar risk factors 
including antibiotic exposure and hospitalization [18]. Previous studies showed the prevalence 
of VRE in CDI subjects is 10-20% [19, 20]. To better identify the specific characteristics of 
the gut microbiota of CDI, it is necessary to compare CDI group with other groups having 
antibiotics exposures and hospitalization such as subjects with VRE colonization.
The purpose of this study was to investigate the characteristics of gut microbiota in patients 
with CDI compared to patients with colitis other than CDI, patients with vancomycin-
resistant enterococci (VRE) colonization, and healthy controls. We expect that the results of 
this investigation may lead to the establishment of novel diagnostic and treatment strategies 
in patients with CDI in Korea.
MATERIALS AND METHODS
1. Study population and sample collection
This study was conducted at a 2,500 beds tertiary hospital of Korea. Stool samples were 
collected from hospitalized patients with CDI (CD+), hospitalized patients with loose stool 
negative for C. difficile (CD−), hospitalized patients with VRE colonisation, and healthy 
controls between December 2014 and March 2015. CD+ and VRE groups included only 
patients who were first diagnosed as CDI or VRE colonization. CDI was diagnosed in subjects 
with diarrhea (passage of three or more unformed or loose stools per day for more than 2 
days) and who satisfied at least one of the following criteria: a toxin-producing C. difficile 
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strain was successfully cultured, or a toxin gene of C. difficile was detected by PCR [21, 22]. 
It was confirmed that subjects in the CD+ and CD− groups did not have VRE colonisation 
within their stool samples. Likewise, subjects in the VRE group were confirmed to be without 
CDI. Subjects with both VRE and CDI were excluded. Healthy controls were recruited 
from individuals visiting the Severance Hospital for routine health check-ups who had no 
malignancy or gastrointestinal disease and no history of antibiotics or chemotherapy for 3 
months prior to investigation. Healthy controls were confirmed to be without CDI or VRE 
colonisation. All of the participants were over 20 years old. The Institutional Review Board 
(IRB) of the Severance Hospital approved the study (IRB #4-2014-0792). The participants for 
this study provided informed signed consent. All methods in this study were performed in 
accordance with the Declaration of Helsinki.
2. Microbiological tests
Stool specimens were cultured to confirm the presence of toxigenic C. difficile. Before 
inoculation, each specimen was pre-treated using the alcohol-shock method, mixed with an 
equivalent volume of alcohol, and incubated for 30 min. Alcohol-shocked specimens were 
inoculated into C. difficile selective agar (BD Co., Franklin Lakes, NJ, USA) and incubated 
at 35°C for 48 h under anaerobic conditions. Colonies suspected of being C. difficile were 
identified using a VITEK 2 automated microbiology system (bioMérieux, Marcy l'Etoile, 
France). After isolating C. difficile, PCR was performed to determine the presence of C. difficile 
toxin genes (tcdA, tcdB, cdtA and cdtB) as previously described [23, 24]. The presence of 
the C. difficile toxin B gene in patient samples was examined by real-time PCR using the 
GeneXpert DX system (Cepheid, Sunnyvale, CA, USA).
The identification of enterococcal growth was performed using the VITEK 2 automated 
system (bioMérieux), and antibiotic susceptibility was determined using a VITEK 2 antibiotic 
susceptibility test card (bioMérieux).
3. DNA extraction
DNA extraction was performed using the QIAamp DNA mini kit (Qiagen, Hilden, Germany) 
according to the manufacturer's instructions. Stool samples stored at −70°C since the day 
of sample collection were used for DNA extraction. First, 500 μg (wet weight) stool sample 
was collected, 10 ml PBS was added, and the solution was vortexed vigorously until the stool 
sample was thoroughly homogenized. Then, the diluted sample was filtered through a cell 
strainer (Falcon, Corning Inc, Corning, NY, USA) and centrifuged at 1,300 rpm for 10 min. 
The sample was resuspended in AL buffer (Qiagen) and disrupted the bacterial cell walls by 
bead-beating according to the manufacturer's recommendations. The quantity and quality of 
DNA was confirmed by measuring the absorbance at 260 and 280 nm using a NanoDrop ND-
1000 spectrophotometer (NanoDrop Technology, Rockland, DE, USA).
4. PCR amplification and pyrosequencing
PCR amplification was performed using primers targeting the V1 to V3 regions of 
the bacterial 16S rRNA gene. For bacterial amplification, barcoded primers of 9F 
(5′-CCTATCCCCTGTGTGCCTTGGCAGTC-TCAG-AC-AGAGTTTGATCMTGGCTCAG-3′; 
underlined sequence indicates the target region primer) and 541R 
(5′-CCATCTCATCCCTGCGTGTCTCCGAC-TCAG-X-AC-ATTACCGCGGCTGCTGG-3′; ‘X’ 
indicates the unique barcode for each subject). Amplification was carried out under the 
following conditions: initial denaturation at 95°C for 5 min, followed by 30 cycles of 95°C 
for 30 s, 55°C for 30s, and 72°C for 30s, with a final elongation at 72°C for 5 min. The PCR 
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product was confirmed by 2% agarose gel electrophoresis and visualized under a Gel Doc 
system (BioRad Laboratories, Hercules, CA, USA). The amplified products were purified with 
the QIAquick PCR purification kit (Qiagen). Equal concentrations of purified products were 
pooled, and short fragments (non-target products) were removed with the Ampure beads kit 
(Agencourt Bioscience, Beverley, MA, USA). The quality and size of the products was assessed 
on a Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA) using a DNA 7500 chip. 
Mixed amplicons were analysed by emulsion PCR, and then deposited on Picotiter plates. 
Sequencing was carried out using the GS Junior Sequencing system (Roche Diagnostics, 
Basel, Switzerland) according to the manufacturer's instructions.
5. Pyrosequencing data analysis
Basic analysis was conducted as described previously [25-27]. The obtained reads from 
the different samples were sorted based on the unique barcodes of each PCR product. The 
sequences of the barcode, linker, and primers were removed from the original sequencing 
reads. Any reads containing two or more ambiguous nucleotides, low-quality reads (average 
score < 25), or reads shorter than 300 bp, were discarded. Potential chimeric sequences were 
detected using the Bellerophon method, which compares the BLASTN search results between 
forward half and reverse half sequences [28]. After removing chimeric sequences, the 
taxonomic classification of each read was assigned against the EzTaxon-e database (http://
eztaxon-e.ezbiocloud.net) [29], which contains the 16S rRNA gene sequences of type strains 
with valid published names and representative species level phylotypes of either cultured 
or uncultured entries in the GenBank database with complete hierarchical taxonomic 
classification from the phylum to the species level. The richness and diversity of samples were 
determined by Chao1 estimation and Shannon diversity index at the 3% distance. Random 
subsampling was conducted to equalize the read size of samples to compare different read 
sizes among samples. The overall phylogenetic distance between communities was estimated 
using Fast UniFrac [30] and visualized using PCoA. To compare operational taxonomic units 
(OTUs) between samples, shared OTUs were obtained by XOR analysis in the CLcommunity 
software (Chunlab Inc., Seoul, Korea).
6. Statistical Analysis
Statistical tests were performed using SPSS version 19 (SPSS Inc., Chicago, IL, USA) and 
CLcommunity (ChunLab Inc.). Data are shown as the mean ± standard deviation (SD). The 
statistical significance of continuous variables was assessed using Student's t-test or the 
Mann-Whitney U test between two groups. One-way analysis of variance (ANOVA) and the 
Kruskal-Wallis test were used to evaluate the differences between more than two groups. A 
value of P <0.05 was considered statistically significant.
RESULTS
1. Characteristics of study subjects
We collected stool samples from hospitalized patients with CD+, hospitalized patients with 
CD−, hospitalized patients with VRE colonization, and healthy controls. A total of sixty-six 
stool samples were collected from twenty-four patients with CD+, eighteen patients with 
CD−, eleven patients with VRE colonization, and thirteen healthy controls. The baseline 
characteristics of each group are shown in Table 1. The mean age was 59.6 years and there 
were 35 male patients (53.0%). The Charlson comorbidity index was the lowest in the healthy 
controls (CD+: 4.2; CD−: 2.1; VRE: 4.1; Healthy: 0.5). The rate of hospitalization in the 3 
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months prior to the investigation was 79.2% in CD+, 44.4% in CD−, 90.9% in VRE, and 0% 
in healthy controls. The mean white blood cell count was highest in the CD+ group (CD+: 
11232.6 (/μL); CD−: 7680.6; VRE: 7147.3; Healthy: 5701.5) and the mean albumin was the 
lowest in the CD+ group (CD+: 3.0 (g/dL); CD−: 3.1; VRE: 3.6; Healthy: 4.2). The clinical 
symptoms of the patients are also shown in Table 1.
The proportion of patients who had used antibiotics in the 3 months prior to this study was 
95.2% in CD+, 83.3% in CD−, and 100% in VRE (Table 2). The total duration of antibiotic use 
was the longest in VRE patients (CD+: 26.2 (days); CD−: 20.9; VRE: 45.2). The duration of 
treatment with each antibiotic class is also shown in Table 2.
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Table 1. Demographic and clinical characteristics of subjects
Characteristics CD+ (n = 24) CD− (n = 18) VRE (n = 11) Healthy (n = 13)
Age 64.8 ± 15.7 62.1 ± 20.2 56.3 ± 23.6 49.2 ± 11.5
Gender (% males) 45.8 55.6 45.5 69.2
BMI (kg/m2) 21.2 ± 3.1 21.1 ± 3.2 20.5 ± 2.8 24.7 ± 3.1
Underlying disease (%)
Cancer 41.7 38.9 36.4 0
Cardiovascular disease 16.7 22.2 27.3 15.4
Diabetes mellitus 20.8 5.6 9.1 15.4
Cerebrovascular disease 41.7 16.7 45.5 0
Chronic lung disease 12.5 11.1 0 7.7
Chronic liver disease 4.2 16.7 9.1 0
Chronic kidney disease 16.7 5.6 45.5 0
Charlson comorbidity index 4.2 ± 2.8 2.1 ± 1.6 4.1 ± 1.6 0.5 ± 0.9
Hospitalization in past 3 months (%) 79.2 44.4 90.9 0
Laboratory findings
White blood cell (/mm3) 11,232.6 ± 7,479.7 7,680.6 ± 5,353.2 7,147.3 ± 2,469.7 5,701.5 ± 1,455.0
Haemoglobin (g/dL) 10.7 ± 2.2 10.5 ± 1.8 10.8 ± 1.7 15.1 ± 1.6
Platelet (/mm3) (×1,000) 239.0 ± 132.1 243.6 ± 181.2 205.7 ± 81.0 223.0 ± 31.0
Albumin (g/dL) 3.0 ± 0.9 3.1 ± 0.5 3.6 ± 0.9 4.2 ± 0.4
CRP (mg/L) 74.7 ± 73.4 31.8 ± 32.4 20.8 ± 16.4
Clinical symptom
Diarrhea 95.8 88.9 18.2
Fever 33.3 22.2 9.1
Vomiting 4.2 0 0
Abdominal pain 12.5 22.2 0
Haematochezia 0 5.6 0
CD, Clostridioides difficile; VRE, vancomycin-resistant enterococci, BMI, body mass index, CRP, C-reactive protein.
Table 2. History of antibiotic use in subjects within 3 months before the start of experiments
CD+ (n = 24) CD− (n = 18) VRE (n = 11) P value
Proportion of subjects with any antibiotic use (%) 95.2 83.3 100.0
Duration of antibiotic use (days, mean ± SD)
Any antibiotics 26.2 ± 22.9 20.9 ± 20.3 45.2 ± 30.5 0.032
Cephalosporin 11.2 ± 11.3 4.6 ± 8.1 11.0 ± 14.1 0.144
Penicillin 5.9 ± 10.9 7.1 ± 10.3 4.8 ± 5.3 0.829
Fluoroquinolone 5.4 ± 9.4 6.7 ± 13.8 11.0 ± 26.7 0.639
Aminoglycoside 0.7 ± 2.0 0 3.1 ± 10.3 0.254
Macrolide 0.3 ± 0.9 0 0 0.248
Carbapenem 4.0 ± 9.3 2.4 ± 5.4 5.8 ± 9.2 0.541
Glycopeptide 2.7 ± 5.6 3.7 ± 7.2 9.4 ± 13.1 0.093
Others 10.2 ± 14.0 7.3 ± 16.2 27.0 ± 34.3
CD, Clostridioides difficile; VRE: vancomycin-resistant enterococci.
2. Species richness and diversity of intestinal microbiota
The alpha diversity of the bacteria in the analysed samples is shown in Table 3 and Fig. 1. The 
species richness, as estimated by the Chao1 index, was significantly lower in the CD+ group 
compared to that in the healthy control (P <0.001), but did not differ significantly between the 
CD+ group and any other group. Microbial diversity, as calculated by the Shannon index, was 
significantly lower in the CD+ group compared to that in the healthy control group (P = 0.001), 
but did not differ significantly between the CD+ group and any other group.
Principal coordinate analysis (PCoA) was used to evaluate the beta diversity within each 
group (Fig. 2). Healthy controls were clustered separately from the CD+, CD−, and VRE 
group, while the CD+, CD−, and VRE groups could not be separated.
3. Relative abundance of intestinal microbes
A comparison of the mean relative abundance of each major phylum is shown in Table 3. 
Phylum Firmicutes was predominant in all groups. In the healthy group, Actinobacteria was 
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Table 3. Alpha diversity and relative abundance within each group at the phylum and genus level
CD+ (n = 24) CD− (n = 18) VRE (n = 11) Healthy (n = 13)
P value
Overalla CD+ vs. healthy
CD+ vs. 
CD−
CD+ vs. 
VRE
Alpha diversity (mean ± SD)
Chao1 index 285.3 ± 190.2 224.0 ± 189.9 251.3 ± 135.5 642.9 ± 219.6 <0.001 <0.001 0.307 0.597
Shannon index 3.6 ± 0.8 3.2 ± 1.2 3.2 ± 0.6 4.5 ± 0.6 0.001 0.001 0.224 0.225
Relative abundance at phylum level (%, mean ± SD)
Firmicutes 73.6 ± 24.4 67.1 ± 33.5 77.2 ± 27.2 78.6 ± 19.8 0.972 0.899 0.889 0.594
Proteobacteria 12.8 ± 23.0 23.6 ± 33.3 17.5 ± 27.3 3.5 ± 7.4 0.849 0.435 0.959 0.644
Bacteroidetes 7.1 ± 11.0 5.9 ± 11.7 2.7 ± 4.6 4.3 ± 8.0 0.673 0.749 0.482 0.693
Actinobacteria 2.8 ± 5.0 3.1 ± 7.8 2.4 ± 6.0 13.6 ± 14.7 0.001 0.001 0.095 0.155
Synergistetes 0.8 ± 2.8 0.2 ± 0.9 0 0.0 ± 0.0 0.323 0.637 0.457 0.227
Verrucomicrobia 2.5 ± 8.0 0.0 ± 0.0 0.0 ± 0.1 0.0 ± 0.0 0.402 0.163 0.357 0.263
Fusobacteria 0.4 ± 1.8 0.1 ± 0.3 0.1 ± 0.3 0.0 ± 0.0 0.958 0.595 0.857 0.797
Relative abundance at genus level (%, mean ± SD)
Blautia 6.9 ± 13.1 2.5 ± 6.6 7.0 ± 14.1 19.1 ± 14.1 <0.001 0.001 0.065 0.390
Bifidobacterium 2.1 ± 5.0 0.8 ± 1.6 2.0 ± 6.1 9.4 ± 11.7 0.001 0.001 0.372 0.369
Lactobacillus 3.6 ± 8.7 2.1 ± 3.8 14.4 ± 25.3 7.2 ± 12.5 0.269 0.084 0.202 0.351
Faecalibacterium 1.3 ± 5.0 1.1 ± 4.4 0.0 ± 0.0 7.0 ± 6.7 <0.001 <0.001 0.483 0.743
Anaerostipes 0.7 ± 1.4 0.2 ± 0.5 0.3 ± 0.8 6.1 ± 9.5 <0.001 0.002 0.389 0.048
Dorea 2.6 ± 6.4 3.0 ± 7.9 0.2 ± 0.5 4.3 ± 2.9 <0.001 <0.001 0.594 0.167
Collinsella 0.1 ± 0.4 0.4 ± 1.1 0.0 ± 0.0 3.6 ± 3.9 0.003 0.003 0.411 0.330
Streptococcus 5.0 ± 12.3 2.5 ± 5.6 6.7 ± 9.9 3.3 ± 8.9 0.617 0.190 0.573 0.406
Escherichia 5.6 ± 13.9 11.0 ± 21.8 7.8 ± 16.8 2.9 ± 7.5 0.830 0.618 0.410 0.665
Eubacterium_g5 0.2 ± 0.7 0.2 ± 0.7 1.5 ± 4.9 2.9 ± 3.1 <0.001 <0.001 0.723 0.661
Fusicatenibacter 0.7 ± 3.1 0.1 ± 0.2 0.0 ± 0.0 2.4 ± 3.0 <0.001 <0.001 0.434 0.741
Prevotella 0.0 ± 0.0 0.0 ± 0.1 0.0 ± 0.0 2.3 ± 5.7 0.004 0.001 0.343 0.884
Roseburia 0.1 ± 0.1 0.1 ± 0.2 0.1 ± 0.2 2.2 ± 2.9 <0.001 <0.001 0.802 0.614
Ruminococcus_g6 2.4 ± 4.8 1.7 ± 6.0 4.9 ± 15.0 2.0 ± 3.7 0.176 0.885 0.092 0.157
Subdoligranulum 0.2 ± 0.6 0.2 ± 0.6 0.0 ± 0.0 2.0 ± 2.0 <0.001 <0.001 0.442 >0.999
GQ871709_g 0.1 ± 0.2 0.1 ± 0.3 0.0 ± 0.0 2.0 ± 1.8 <0.001 <0.001 0.630 0.157
Catenibacterium 0.0 ± 0.0 0.1 ± 0.4 0.0 ± 0.0 2.0 ± 3.6 0.001 0.001 0.248 >0.999
Clostridium 0.2 ± 0.4 0.2 ± 0.6 0.4 ± 1.1 1.8 ± 2.7 0.047 0.035 0.784 0.344
Ruminococcus_g2 0.1 ± 0.6 0.0 ± 0.1 0.1 ± 0.2 1.7 ± 2.9 <0.001 <0.001 0.469 0.797
Dialister 0.0 ± 0.1 0.1 ± 0.2 0.0 ± 0.0 1.6 ± 3.2 0.003 0.002 0.181 0.331
Eubacterium_g2 0.7 ± 3.5 0.8 ± 3.2 0.0 ± 0.0 1.1 ± 3.0 0.308 0.218 0.416 0.331
Ruminococcus_g5 0.2 ± 0.5 0.2 ± 0.4 0.0 ± 0.0 1.0 ± 1.2 <0.001 <0.001 0.440 0.392
Bacteroides 6.2 ± 10.5 3.0 ± 5.5 2.6 ± 4.4 1.0 ± 1.4 0.527 0.747 0.195 0.404
aOverall P value shows P values calculated by one-way analysis of variance (ANOVA) or Kruskal-Wallis test to evaluate the differences between CD+, CD−, VRE, 
and healthy groups.
CD, Clostridioides difficile; VRE, vancomycin-resistant enterococci.
the second-most abundant. The abundance of Actinobacteria was significantly lower in the 
CD+ group (P = 0.001) compared to that in healthy control, but there was no difference 
in its abundance between the CD+ group and any other group. Proteobacteria was the 
second-most predominant phylum in the CD+, CD−, and VRE groups. The proportion of 
Proteobacteria was slightly higher in the CD+, CD−, and VRE groups than in healthy controls, 
but not significantly (12.8% in CD+; 23.6% in CD−; 17.5% in VRE; 3.5% in healthy control). 
Compared to that in the VRE group, the proportion of Bacteroidetes was higher in the CD+ and 
CD− groups, but not significantly (7.1% in CD+; 5.9% in CD−; 2.7% in VRE; 4.3% in healthy 
control, P = 0.673). Verrucomicrobia was detected at a proportion of 2.5% in the CD+ group, but 
was below the detection threshold in the CD−, VRE, and healthy groups.
At the genus level, genera with a mean relative abundance of >1.0% (based on healthy 
controls) were analysed, as described in Table 3. Compared to those in the healthy 
group, the CD+ group showed significantly lower proportions of Blautia, Bifidobacterium, 
Faecalibacterium, Anaerostipes, Dorea, Collinsella, Eubacterium_g5, Fusicatenibacter, Prevotella, 
Roseburia, Subdoligranulum, GQ871709_g, Catenibacterium, Clostridium, Ruminococcus_g2, Dialister, 
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Figure 1. Alpha diversity of analysed bacterial samples. (A) Chao1 index to determine species richness. (B) Shannon 
index to determine microbial diversity. 
CD+, hospitalized patients with Clostridioides difficile infection; CD−, hospitalized patients with colitis not due to 
C. difficile; VRE, hospitalized patients with vancomycin-resistant enterococci colonisation.
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Figure 2. Principal coordinate analysis (PCoA) was used to evaluate the beta diversity of each group of bacteria. 
CD+, hospitalized patients with Clostridioides difficile infection; CD−, hospitalized patients with colitis not due to 
C. difficile; VRE, hospitalized patients with vancomycin-resistant enterococci colonisation.
and Ruminococcus_g5. However, the proportions of Streptococcus, Escherichia, and Bacteroides in 
the CD+ group were higher than those in the healthy control, but not significantly. Compared 
to those in the CD− group, subjects in the CD+ group showed no significant difference in the 
abundance of any bacteria at the genus level. Compared to those in the VRE group, subjects 
in the CD+ group showed a significantly higher proportion of Anaerostipes. 
DISCUSSION
This study evaluated the characteristics of faecal microbiota in patients with C. difficile-
associated diarrhea. It is well known that the disruption of the gut microbiota is a major cause 
of CDI, and previous studies have consistently shown that a reduction in the diversity and 
abundance of faecal microbiota is a common phenomenon in CDI patients [31-33]. Exposure to 
antibiotics is a major cause of gut microbiota disruption and CDI. Antibiotic use also promotes 
and maintains a high density of enterococci, including VRE [34, 35]. To better characterize 
changes in the gut microbiota due to CDI, we included VRE-colonised subjects in addition to 
healthy controls and subjects with CD− loose stool. Although CDI subjects showed a lower 
bacterial richness and diversity than the healthy controls, the species richness and diversity 
of intestinal microbiota was not significantly different in the CD+, CD−, and VRE groups. 
Patients in these groups had similar levels of antibiotic exposure, and antibiotic exposure itself 
is known to decrease bacterial richness and diversity, regardless of CD toxin positivity or VRE 
colonisation. In our comparison of the composition of bacterial phyla and genera between 
groups, there was also no observable difference in composition between the CD+, CD−, 
and VRE groups. Taken together, this study could not find any differences in the microbiota 
between CD+, CD−, and VRE patients with similar histories of antibiotic exposure.
FMT has become an effective treatment for recurrent CDI [12, 36]. Recently, FMT has been 
attempted to eliminate intestinal colonisation by multi-drug resistant organisms (MDRO) 
such as extended spectrum β-lactamase (ESBL)-producing and carbapenemase-producing 
Enterobacteriaceae (CPE), VRE, and methicillin-resistant Staphylococcus aureus (MRSA) [37-39]. 
These attempts have shown considerable successes, and FMT has emerged as a promising 
therapy for intestinal MDRO decolonisation. The identification of any key microbiome 
components associated with CDI or VRE would allow researchers to apply this microbiome 
factor to develop more specific probiotics to treat dysbiosis. Although we could not find 
any specific phyla to differentiate between CDI and VRE colonisation, the proportion of 
Verrucomicrobia was slightly higher in the CD+ group, and Synergistetes was detected only 
in the CD+ group, but not in the VRE group. At the genus level, the CD+ group showed a 
significantly higher proportion of Anaerostipes compared to that in the VRE group.
Consistent with previous studies, decreased diversity and richness were characteristic 
of the microbiota in CDI patients compared to those in healthy controls [33]. However, 
the microbial composition at the phylum and genus levels for CDI patients was not fully 
consistent with previous results. A recent study in Korea compared the composition of the 
gut microbiota in patients with toxigenic CDI and healthy controls [33]. They showed that 
the proportion of Proteobacteria was significantly higher in CDI than in healthy controls at 
the phylum level, and several genera, such as Phascolarctobacterium, Lachnospira, Butyricimonas, 
Catenibacterium, Paraprevotella, Odoribacter, and Anaerostipes, were not detected in most CDI 
patients. Decreased Bacteroidetes and increased Proteobacteria in CDI have been observed in 
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previous studies [32, 40]. In our study, the proportion of Proteobacteria was insignificantly 
higher in CD+ patients than in healthy controls, and the proportion of Actinobacteria was 
significantly lower in the CD+ group compared to that in healthy controls. The proportion 
of Bacteroidetes was not significantly different between CD+ group and healthy control. 
Bacteroidetes was the third-most predominant phylum in our study, but was the second-
most predominant phylum in CDI samples in the previous study. The identified intestinal 
microbiome characteristics of Koreans with CDI compared to other patients with antibiotic 
exposure and healthy control might help to develop microbiome based diagnostic and 
treatment modalities.
This study had several limitations. First, the small number of subjects was a major limitation 
in this study. Second, we could not control the effects of sample storage and interval between 
sample collection and DNA extraction on the analysis of microbiome. Third, we could not 
adjust confounding factors such as antibiotic use, hospital days, comorbidities, etc. which 
may affect the microbiota of subjects. Fourth, we could not compare the characteristics of 
microbiota according to the type of C. difficile toxin and the genotype of VRE. Furthermore, we 
could not evaluate paired samples to compare microbiome characteristics before and after 
CDI. The diet of the subjects may also have affected the characteristics of the microbiome, 
but we could not collect data to investigate this.
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